Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:14:30 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:CRNX - CRINETICS PHARMACEUTICALS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CRNX - Q5.031.11·31.650.931.11-1.91-5.8923.528,8768,89833.07  33.22  30.8462.53  24.1018:05:38Jul 1315 min RT 2¢

Recent Trades - Last 10 of 8898
Time ETExPriceChangeVolume
18:05:38Q31.99-1.0350
17:41:34Q31.124-1.89625
16:57:26Q31.00-2.0210
16:53:46Q31.1086-1.91143
16:33:15Q31.11-1.915,430
16:20:00Q31.11-1.91353
16:04:12Q31.11-1.911
16:04:12Q31.11-1.911
16:04:02Q31.11-1.911
16:02:37Q31.11-1.9123

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-13 17:45U:CRNXNews ReleaseCrinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY(TM) (Paltusotine) in Acromegaly at ENDO 2025
2025-07-11 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-07-10 16:29U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-30 16:05U:CRNXNews ReleaseCrinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
2025-06-16 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Host R&D Day on June 26, 2025
2025-06-10 16:30U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-23 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
2025-05-15 16:05U:CRNXNews ReleaseCrinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
2025-05-12 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-08 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
2025-04-11 08:00U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
2025-04-10 17:04U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-27 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
2025-03-10 16:36U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-24 08:30U:CRNXNews ReleaseCrinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
2025-02-20 16:05U:CRNXNews ReleaseCrinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
2025-02-10 16:44U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-06 16:35U:CRNXNews ReleaseCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
2025-01-10 17:15U:CRNXNews ReleaseCrinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)